Patents by Inventor Bracken M. King

Bracken M. King has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid encoding chimeric IL-1 receptor type I antagonists
    Patent number: 9458216
    Abstract: Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, ? strands, and loops from at least two parental cytokines domains.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: October 4, 2016
    Assignee: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Thomas M. Barnes, Jinzhao Hou, Bracken M. King
  • CHIMERIC IL-1 RECEPTOR TYPE I AGONISTS AND ANTAGONISTS
    Publication number: 20150087818
    Abstract: Featured herein are non-naturally occuring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, ? strands, and loops from at least two parental cytokines domains.
    Type: Application
    Filed: August 15, 2014
    Publication date: March 26, 2015
    Inventors: Thomas M. Barnes, Jinzhao Hou, Bracken M. King
  • Chimeric IL-1 receptor type I antagonists
    Patent number: 8853150
    Abstract: Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1 RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, ? strands, and loops from at least two parental cytokines domains.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: October 7, 2014
    Assignee: Eleven Biotherapeutics, Inc.
    Inventors: Thomas M. Barnes, Jinzhao Hou, Bracken M. King
  • CHIMERIC IL-1 RECEPTOR TYPE I AGONISTS AND ANTAGONISTS
    Publication number: 20130209396
    Abstract: Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1 RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, ? strands, and loops from at least two parental cytokines domains.
    Type: Application
    Filed: July 29, 2011
    Publication date: August 15, 2013
    Applicant: ELEVEN BIOTHERAPEUTICS, INC.
    Inventors: Thomas M. Barnes, Jinzhao Hou, Bracken M. King
  • IL-17 FAMILY CYTOKINE COMPOSITIONS AND USES
    Publication number: 20130064788
    Abstract: Binding proteins, including non-naturally occurring and recombinantly modified proteins that bind to an IL-17R and including proteins having a mutated IL-17 cytokine sequence, methods of making such molecules and methods of using such molecules as therapeutic, prophylactic and diagnostic agents are provided.
    Type: Application
    Filed: October 11, 2010
    Publication date: March 14, 2013
    Applicants: Eleven Biotherapeutics, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Thomas M. Barnes, Michael M. Schmidt, Bracken M. King, K. Christopher Garcia, Sashank Reddy, Gregory James Sieczkiewicz, Lauren K. Ely